Innovative Treatment for a Pipeline of Inflammatory Indications

CTO1681: Orally bioavailable, steroid sparing immunomodulator
for multiple indications driven by cytokine inducing inflammation
Learn More

Our Vision

Immune hyperactivation and dysregulation are key drivers of disease pathogenesis and complications across oncology and inflammatory diseases, specifically in the tumor microenvironment, as well as in asthma, COPD, and atopic dermatitis. Hyperactivation of the immune system limits efficacy of cell therapies and causes life threatening treatment-related toxicities. Greater than 60% of acute exacerbations in asthma and COPD are driven by viral infections that further drive prostaglandin and prostacyclin-mediated inflammation. Similarly, greater than 90% of atopic dermatitis patients are colonized with S. Aureus and many are complicated with concomitant viral/fungal infections that drive disease flares and progression.

CTO1681 aims to solve this problem by providing a safe, effective and orally bioavailable immunomodulator that will help overcome the inflammation driving illness. CTO1681 is a novel, steroid sparing inhibitor of prostaglandin/prostacyclin-mediated inflammation. Our mission is to enable greater accessibility, lower costs, increased clinical adoption, and most importantly better outcomes for all patients.

Our Science

Inflammation Driving Multiple Diseases

Inflammation in the tumor microenvironments driven by inflammatory cytokines
High CRS and ICANS incidence requires 12-14 days average hospitalization with 33% sent to ICU
60% of acute asthma exacerbations are driven by viral infections that further drive prostaglandin and prostacyclin mediated inflammation
90% of atopic dermatitis patients are colonized bacterial and fungal infections that drive inflammation

Pipeline of Inflammatory Indications

CTO1681 Clinical Development
CAR T-Cell and TCE Therapy-Related Inflammation

CytoAgents is conducting its Phase 1b/2a clinical trial aimed at reducing inflammation in patients receiving CAR T-Cell Therapy in oncology. CAR T therapies face a dual challenge in oncology indications. First, inflammation in the tumor microenvironment may limit the CAR T from properly expanding and effectively killing cancer cells. Second, immunotherapies such as CAR T and TCE therapy trigger powerful immune responses to fight disease, which often induces cytokine driven toxicities such as CRS and ICANS. CTO1681’s ability to safely modulate the cytokine response while keeping the immune system functionally intact makes it an ideal solution in this setting.

Learn More

CTO1681:
Prostaglandin Inhibitor reduces PGE2 Signaling and modulates 20+ key cytokines

Our Science

MODULATING INFLAMMATION & CYTOKINE AMPLIFICATION

Many illnesses develop when unchecked cytokine production leads to a cycle of inflammation. CTO1681, an oral prostaglandin inhibitor treats the underlying causes of inflammation by blocking the NF-kB and PGE2 signaling pathways that play a critical role in activating and regulating inflammatory immune cells. By interrupting these signaling pathways CTO1681 effectively blocks cytokine amplification, downregulating cytokine production while leaving the immune system functionally intact.

Learn More

Partners & Investors

CytoAgents has made tremendous progress in controlling cytokine driven inflammation. We have successfully completed our initial Phase 1 Human Clinical Trial and are currently enrolling a Phase 1b/2a Clinical Trial in patients receiving CAR T-cell therapy at risk for cytokine driven overwhelming inflammation.

Join us as we transform inflammation through a novel approach that allows for prevention as well as treatment.

FCOI NIH Disclosure